JP2021510702A5 - - Google Patents
Info
- Publication number
- JP2021510702A5 JP2021510702A5 JP2020538844A JP2020538844A JP2021510702A5 JP 2021510702 A5 JP2021510702 A5 JP 2021510702A5 JP 2020538844 A JP2020538844 A JP 2020538844A JP 2020538844 A JP2020538844 A JP 2020538844A JP 2021510702 A5 JP2021510702 A5 JP 2021510702A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- product according
- conjugate
- pharmaceutical product
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186470A JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617095P | 2018-01-12 | 2018-01-12 | |
| US62/617,095 | 2018-01-12 | ||
| US201862674483P | 2018-05-21 | 2018-05-21 | |
| US62/674,483 | 2018-05-21 | ||
| US201862700147P | 2018-07-18 | 2018-07-18 | |
| US62/700,147 | 2018-07-18 | ||
| US201862711421P | 2018-07-27 | 2018-07-27 | |
| US201862711423P | 2018-07-27 | 2018-07-27 | |
| US62/711,423 | 2018-07-27 | ||
| US62/711,421 | 2018-07-27 | ||
| US201862716796P | 2018-08-09 | 2018-08-09 | |
| US201862716788P | 2018-08-09 | 2018-08-09 | |
| US62/716,796 | 2018-08-09 | ||
| US62/716,788 | 2018-08-09 | ||
| PCT/US2019/013314 WO2019140271A2 (en) | 2018-01-12 | 2019-01-11 | Synergistic cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186470A Division JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021510702A JP2021510702A (ja) | 2021-04-30 |
| JP2021510702A5 true JP2021510702A5 (https=) | 2022-01-19 |
Family
ID=67218383
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538844A Pending JP2021510702A (ja) | 2018-01-12 | 2019-01-11 | 相乗的がん治療 |
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20200360545A1 (https=) |
| EP (2) | EP3737416A4 (https=) |
| JP (3) | JP2021510702A (https=) |
| KR (2) | KR20200109345A (https=) |
| CN (2) | CN111587115A (https=) |
| AU (2) | AU2019206623A1 (https=) |
| CA (2) | CA3087967A1 (https=) |
| MX (3) | MX2020007442A (https=) |
| RU (1) | RU2020126774A (https=) |
| WO (2) | WO2019140266A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| CA3151529A1 (en) * | 2019-08-28 | 2021-03-04 | Prolynx Llc | Conjugated inhibitors of dna damage response |
| JPWO2023199723A1 (https=) * | 2022-04-14 | 2023-10-19 | ||
| US20260041680A1 (en) * | 2022-08-04 | 2026-02-12 | Prolynx Llc | Methods of treating cancer with long-acting topoisomerase i inhibitor |
| US20260034120A1 (en) * | 2022-08-04 | 2026-02-05 | Prolynx Llc | Treating cancer with long-acting topoisomerase i inhibitor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2319854B1 (en) | 1997-01-08 | 2016-11-30 | Sigma-Aldrich Co. LLC | Bioconjugation Of Macromolecules |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| JP2005537266A (ja) | 2002-07-12 | 2005-12-08 | バイオマリン ファーマシューティカル インコーポレイテッド | 加水分解性活性物質であるバイオポリマーコンジュゲートを作製するためのイソシアネートリンカーの使用 |
| AU2003280592B2 (en) | 2002-10-31 | 2008-12-18 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| CA2537336C (en) | 2003-09-17 | 2013-02-26 | Nektar Therapeutics Al, Corporation | Multi-arm polymer prodrugs |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| JP2010503708A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | 多官能性リンカーを含む標的化ポリマープロドラッグ |
| US8586019B2 (en) * | 2008-05-22 | 2013-11-19 | Ramot At Tel-Aviv University Ltd. | Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
| ES2672526T3 (es) | 2008-06-26 | 2018-06-14 | Prolynx Llc | Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas |
| KR20110075029A (ko) | 2008-10-21 | 2011-07-05 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료 |
| AU2009316749A1 (en) | 2008-11-18 | 2011-06-30 | Baxter Healthcare S.A. | Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample |
| AU2010254013A1 (en) | 2009-05-28 | 2011-11-24 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| PT2501413T (pt) * | 2009-11-18 | 2019-07-10 | Nektar Therapeutics | Formas de sal de ácido de conjugados de polímero-fármaco |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| US8703907B2 (en) | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
| TW201215412A (en) | 2010-08-30 | 2012-04-16 | Sun Pharma Advanced Res Co Ltd | Stable pharmaceutical composition |
| RU2017127088A (ru) | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| EP2654795B1 (en) | 2010-12-21 | 2018-03-07 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CN104244988A (zh) | 2012-03-05 | 2014-12-24 | 雷蒙特亚特特拉维夫大学有限公司 | 结合治疗活性剂的聚合物、其制备方法以及其用途 |
| TWI486341B (zh) | 2012-05-18 | 2015-06-01 | 高雄醫學大學 | 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法 |
| WO2014194289A1 (en) * | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| MX371201B (es) | 2013-10-04 | 2020-01-22 | Prolynx Llc | Conjugados de liberación lenta de sn-38. |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015118338A1 (en) | 2014-02-07 | 2015-08-13 | Mission Therapeutics Limited | Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways |
| WO2015183876A1 (en) * | 2014-05-28 | 2015-12-03 | Memorial Sloan Kettering Cancer Center | Bimodal fluorophore-labeled liposomes and associated methods and systems |
| JP6342575B2 (ja) * | 2014-08-13 | 2018-06-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 脳腫瘍への選択的デンドリマー送達 |
| US20160067362A1 (en) | 2014-08-16 | 2016-03-10 | Memorial Sloan Kettering Cancer Center | Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods |
| JP6378584B2 (ja) | 2014-08-29 | 2018-08-22 | キヤノン株式会社 | 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム |
| US10196412B2 (en) * | 2014-12-24 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Probe for imaging PARP-1 activity |
| RS62082B1 (sr) | 2015-04-02 | 2021-08-31 | Merck Patent Gmbh | Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze |
| JP6869187B2 (ja) * | 2015-04-07 | 2021-05-12 | メモリアル スローン ケタリング キャンサー センター | ナノ粒子イムノコンジュゲート |
| US10973925B2 (en) * | 2015-04-28 | 2021-04-13 | University Of Central Florida Research Foundation Inc. | Methods and compositions for theranostic nanoparticles |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| US10821195B2 (en) | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| EP3423048A4 (en) | 2016-02-29 | 2019-10-23 | Synta Pharmaceuticals Corp. | COMBINATION THERAPY FOR THE TREATMENT OF EGG CANCER |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| AU2017257254B2 (en) | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| WO2017189961A1 (en) | 2016-04-29 | 2017-11-02 | Memorial Sloan Kettering Cancer Center | Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors |
| CN106084005B (zh) | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| CN107050471A (zh) * | 2016-12-27 | 2017-08-18 | 中国药科大学 | 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用 |
-
2019
- 2019-01-11 MX MX2020007442A patent/MX2020007442A/es unknown
- 2019-01-11 AU AU2019206623A patent/AU2019206623A1/en not_active Abandoned
- 2019-01-11 JP JP2020538844A patent/JP2021510702A/ja active Pending
- 2019-01-11 AU AU2019208024A patent/AU2019208024A1/en not_active Abandoned
- 2019-01-11 CN CN201980008227.1A patent/CN111587115A/zh active Pending
- 2019-01-11 MX MX2020007306A patent/MX2020007306A/es unknown
- 2019-01-11 EP EP19738881.2A patent/EP3737416A4/en not_active Withdrawn
- 2019-01-11 CA CA3087967A patent/CA3087967A1/en active Pending
- 2019-01-11 EP EP19738883.8A patent/EP3737383A4/en not_active Withdrawn
- 2019-01-11 US US16/961,633 patent/US20200360545A1/en not_active Abandoned
- 2019-01-11 KR KR1020207023338A patent/KR20200109345A/ko not_active Ceased
- 2019-01-11 WO PCT/US2019/013306 patent/WO2019140266A1/en not_active Ceased
- 2019-01-11 CA CA3087628A patent/CA3087628A1/en active Pending
- 2019-01-11 CN CN201980008252.XA patent/CN111587126A/zh active Pending
- 2019-01-11 US US16/961,640 patent/US11730836B2/en active Active
- 2019-01-11 KR KR1020207023337A patent/KR20200110377A/ko not_active Ceased
- 2019-01-11 JP JP2020538819A patent/JP2021510701A/ja active Pending
- 2019-01-11 RU RU2020126774A patent/RU2020126774A/ru unknown
- 2019-01-11 WO PCT/US2019/013314 patent/WO2019140271A2/en not_active Ceased
-
2020
- 2020-07-13 MX MX2023005786A patent/MX2023005786A/es unknown
-
2023
- 2023-03-07 US US18/118,650 patent/US20230321286A1/en not_active Abandoned
- 2023-07-11 US US18/220,742 patent/US20240082436A1/en not_active Abandoned
- 2023-10-31 JP JP2023186470A patent/JP7703001B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021510702A5 (https=) | ||
| Bonelli et al. | Precision medicine in gastric cancer | |
| Chen et al. | Improving radiotherapy in cancer treatment: Promises and challenges | |
| Aghajanian et al. | Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer | |
| Bloy et al. | Trial watch: radioimmunotherapy for oncological indications | |
| Drost et al. | Opportunities and hurdles in the treatment of BRCA1-related breast cancer | |
| Mauclet et al. | Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| JP2017519006A5 (https=) | ||
| WO2010063011A3 (en) | Methods for the treatment of infections and tumors | |
| JP2012529021A5 (https=) | ||
| WO2012061683A3 (en) | Methods for treating cancer | |
| JP2012528890A5 (https=) | ||
| JP2017503842A5 (https=) | ||
| Arrighetti et al. | Drug combinations with HDAC inhibitors in antitumor therapy | |
| Cutsem et al. | The role of chemotherapy in the current treatment of gastric cancer | |
| Crinò et al. | Present and future treatment of advanced non–small cell lung cancer | |
| Miao et al. | Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway | |
| AU2017324860A1 (en) | PD-1 specific aptamers | |
| Voigtlaender et al. | Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism | |
| Folprecht | Liver metastases in colorectal cancer | |
| Voorhees et al. | Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma | |
| US20220288404A1 (en) | Methods for applying tumor treating fields in combination with cancer treating therapeutics | |
| Sandler et al. | Lung cancer: a review of current therapeutic modalities | |
| DiPasco et al. | The thrombophilic state in cancer part II: cancer outcomes, occult malignancy, and cancer suppression |